Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Cann Group to get a boost from Australia’s new medical cannabis export policy

Cann is planning to develop a 16,000 square metre medicinal canabbis facility.
Cann Group to get a boost from Australia’s new medical cannabis export policy
Cann recently commissioned its second production facility

Cann Group Ltd (ASX:CAN) is expected to benefit from the Australian Federal Government’s decision to permit Australian producers of medicinal cannabis to export products to overseas markets.

The company’s shares are trading circa 15% higher intra-day, at $3.32.

The federal government has approved the exportation of medicinal cannabis in a bid to strengthen the supply amid growing demand domestically and worldwide.

Importantly, the decision to allow exports is expected to lead to further investment in the Australian industry and provide local companies with an incentive to accelerate their development plans.

Cann recently commissioned its second production facility, and is progressing plans to develop a 16,000 square metre cultivation, R&D and manufacturing facility as part of its phase III expansion.

The expanded capacity is aimed at serving the Australian market with a reliable supply of high quality, safe and innovative medicinal cannabis products.

Well funded for expansion plans

In December 2017, the company successfully completed a share placement to institutional, sophisticated and professional investors to raise $58.7 million at $2.50 per share.

Major shareholder Aurora Cannabis Inc (TSE:ACB) participated in the placement and committed to invest a total of up to circa $26 million to achieve a 22.9% shareholding.

Cann is now in a strong position to accelerate its plans to substantially expand cultivation capacity, to support additional clinical trial activity and to continue its product development.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full CAN profile View Profile

Related Articles

1534822132_cadoux.jpg
August 21 2018
The company aims to revolutionise the HPA production process, eschewing the laborious bauxite-sourced method.
1530537220_Blood-Test.jpg
July 02 2018
The research and diagnostic company develops cancer-detecting blood tests
Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use